" class="no-js "lang="en-US"> Chroma Medicine - Medtech Alert
Friday, April 19, 2024
Chroma Medicine | Pharmtech Focus

Chroma Medicine

About Chroma Medicine

Chroma Medicine

Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, revolutionizing the treatment of genetically driven diseases.

The epigenome is nature’s gatekeeper for gene expression, governing cell phenotype and function by precisely controlling gene activity without changing the underlying DNA sequence. Building on groundbreaking research from the world’s foremost genomic medicine experts, Chroma Medicine is working at the cutting edge of precision genomics, building an entirely new class of therapeutics to achieve unparalleled control of gene expression.

Related Story

Chroma Medicine Announces Data Demonstrating the Benefits of Epigenetic Editing for Multiplex Gene Regulation

May 19 2023

Chroma Medicine, a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today presented data demonstrating […]

Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology

March 1 2023

Chroma Medicine, a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced the completion […]

Chroma Medicine Launches with $125M in Financing to Deliver on the Promise of Epigenetic Editing

November 17 2021

Chroma Medicine, Inc., (Chroma) a new genomic medicine company pioneering epigenetic editing, launched today with $125M in […]